Dihexyl phthalate
Based on 1 publication(s) in Google Scholar
Dihexyl phthalate is an orally active phthalate ester (PAEs) widely used as a plasticizer, and it acts as an environmental endocrine disruptor. Dihexyl phthalate exhibits endocrine-disrupting and reproductive toxic properties, induces oxidative stress and inflammation, and ultimately causes apoptosis and damage to reproductive organs such as the testes. Dihexyl phthalate can be used in studies related to developmental toxicity, embryonic lethality, teratogenicity, and abnormal development of the male reproductive system.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.73%
- CAS No.: 84-75-3
- Formule: C20H30O4
- Masse moléculaire:334.46
-
Stockage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-W013755
Dioctyl phthalatePlasticizer -
HY-B1945
DEHPEndogenous Metabolite -
HY-Y0304
Dibutyl phthalatePlasticizer -
HY-B1945R
DEHP (Standard)Endogenous Metabolite -
HY-W011215R
Dihexyl phthalate (Standard)Reference Standard -
HY-W011338
Benzyl butyl phthalateAhR Activator -
HY-W009142
Dicyclohexyl phthalatePlasticizer -
HY-N0349
Methyl parabenBacterial Inhibitor -
HY-Y0284
Diethyl phthalatePlasticizer -
HY-B1431
ButylparabenBacterial Inhibitor -
HY-W013816
Dipentyl phthalatePlasticizer
Publications Citing Use of MedChemExpress (MCE) Dihexyl phthalate
More
Activité biologique
Description
In Vitro
Dihexyl phthalate (100 μg/mL; 10 min at 37°C) inhibits phenoloxidase activity in hemocytes of Macrobrachium rosenbergii and reduces the production of superoxide anions in hemocytes[3].
Dihexyl phthalate (100 μg/mL; ≥10 min) induces time-dependent morphological changes and apoptosis in hemocytes of Macrobrachium rosenbergii[3].
Dihexyl phthalate (1-10 μg/L; 6-24 h) promotes biofilm formation, increases biomass, and enhances resistance to sodium hypochlorite disinfectant in Pseudomonas aeruginosa biofilms; it upregulates the expression of quorum sensing-related genes, bacterial adhesion genes, EPS secretion genes, and antioxidant system genes; significantly increases the production of polysaccharides, extracellular DNA, and proteins; and increases biofilm density, elevates the live/dead cell ratio, as well as increases elastic modulus and surface roughness[4].
Dihexyl phthalate (1-10 μg/L; 3 h) increases intracellular reactive oxygen species (ROS) levels in planktonic Pseudomonas aeruginosa[4].
Dihexyl phthalate (1-10 μg/L) increases cellular ATP activity, enhances the activities of superoxide dismutase and catalase, elevates glutathione concentration, and reduces the overall reactive oxygen species (ROS) level in Pseudomonas aeruginosa biofilms[4].
Dihexyl phthalate (100 μg/mL; 10 min) inhibits adhesion and pseudopodium formation of hemocytes from Macrobrachium rosenbergii, reducing the proportion of adherent cells to 85.0% of that in the control group and the proportion of pseudopodium-forming cells to 17.6% of that in the control group[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Pseudomonas aeruginosa PAO1
-
Concentration:1, 2, 5, 10 μg/L
-
Incubation Time:6 h
-
Result:Significantly upregulated the expression of genes associated with quorum sensing secretion (lasI, lasR, rhlI, rhlR), bacterial adherence (sagS), EPS excretion (pslA, pelA), and the antioxidative system (sodM, msrB).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (female primiparous, 180-200 g, pregnant exposed during gestational days 6-20)[2]
-
Dosage:250 mg/kg; 500 mg/kg; 750 mg/kg
-
Administration:p.o.; once daily; gestational days 6-20
-
Result:Caused maternal toxicity at 750 mg/kg/day, evidenced by significant reductions in maternal food consumption and body weight gain.
Caused a slight but significant increase in liver weight and induced cyanide-insensitive palmitoyl-CoA oxidation activity (a peroxisomal enzyme marker).
Caused a high incidence of post-implantation loss (severe embryolethality) at 750 mg/kg/day.
Caused a significant decrease in fetal body weight and induced external, visceral, and skeletal malformations (mainly including cleft palate, eye defects, and axial skeleton abnormalities) at 500 and 750 mg/kg/day.
Caused a dose-related, significant reduction in the anogenital distance (AGD) of male fetuses at all doses (250, 500, 750 mg/kg/day).
Increased the incidence of undescended testes in male fetuses at 500 and 750 mg/kg/day.
Chemical Information
-
CAS No. 84-75-3
-
Appearance Liquid (Density: 1.0±0.1 g/cm3)
-
Masse moléculaire 334.46
-
Formule C20H30O4
-
Color Colorless to light yellow
-
SMILES
O=C(OCCCCCC)C1=CC=CC=C1C(OCCCCCC)=O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
In Vitro:
DMSO : 83.33 mg/mL (249.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.47 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (288 KB)
-
SDS (478 KB)
- English - EN (478 KB)
- Français - FR (478 KB)
- Deutsch - DE (478 KB)
- Norwegian - NO (478 KB)
- Español - ES (478 KB)
- Swedish - SV (478 KB)
- Italian - IT (478 KB)
- Korean - KR (478 KB)
- Portuguese - PT (478 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9899 mL | 14.9495 mL | 29.8989 mL | 74.7474 mL |
| 5 mM | 0.5980 mL | 2.9899 mL | 5.9798 mL | 14.9495 mL | |
| 10 mM | 0.2990 mL | 1.4949 mL | 2.9899 mL | 7.4747 mL | |
| 15 mM | 0.1993 mL | 0.9966 mL | 1.9933 mL | 4.9832 mL | |
| 20 mM | 0.1495 mL | 0.7475 mL | 1.4949 mL | 3.7374 mL | |
| 25 mM | 0.1196 mL | 0.5980 mL | 1.1960 mL | 2.9899 mL | |
| 30 mM | 0.0997 mL | 0.4983 mL | 0.9966 mL | 2.4916 mL | |
| 40 mM | 0.0747 mL | 0.3737 mL | 0.7475 mL | 1.8687 mL | |
| 50 mM | 0.0598 mL | 0.2990 mL | 0.5980 mL | 1.4949 mL | |
| 60 mM | 0.0498 mL | 0.2492 mL | 0.4983 mL | 1.2458 mL | |
| 80 mM | 0.0374 mL | 0.1869 mL | 0.3737 mL | 0.9343 mL | |
| 100 mM | 0.0299 mL | 0.1495 mL | 0.2990 mL | 0.7475 mL |
Dihexyl phthalate Related Classifications
HY-W011215 Related Classifications
Powered by Bioz
Keywords
- Dihexyl phthalate
- 84-75-3
- Apoptosis
- Reactive Oxygen Species (ROS)
- teratogenicity
- phenoloxidase
- hemocyte apoptosis
- Sprague-Dawley rats
- giant freshwater prawn hemocytes
- male reproductive system developmental abnormalities
- embryolethality
- Pseudomonas aeruginosa PAO1
- biofilm formation
- developmental toxicity
- Inhibitor
- inhibitor
- inhibit